The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

ARIAD to Present at the Bank of America Merrill Lynch 2011 Health Care Conference

Wednesday, May 04, 2011

ARIAD to Present at the Bank of America Merrill Lynch 2011 Health Care Conference07:35 EDT Wednesday, May 04, 2011 CAMBRIDGE, Mass. (Business Wire) -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Bank of America Merrill Lynch Health Care Conference being held at the Encore At Wynn in Las Vegas, Nevada. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company's strong oncology pipeline on Wednesday, May 11, 2011 at 11:20 a.m. (PDT). The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at http://www.ariad.com/investor. A replay of the presentation will be available on the ARIAD website approximately one hour after the presentation and will be archived for two weeks. About ARIAD ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need - aggressive cancers where current therapies are inadequate. ARIAD's product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck that has successfully completed a Phase 3 clinical trial in patients with soft-tissue and bone sarcomas and is being studied in multiple cancer indications. ARIAD's second internally discovered product candidate, ponatinib, is an investigational pan-BCR-ABL inhibitor in a pivotal Phase 2 clinical trial in patients with chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. For additional information, please visit www.ariad.com. ARIAD Pharmaceuticals, Inc.Maria E. Cantor, 617-621-2208